ArticleClinical and translational science2025
Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood-brain barrier disruption.
Article in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluation of cerebrospinal fluid penetration of delafloxacin in a murine model.Antimicrobial agents and chemotherapy · 2026Article
- Insufficient cerebrospinal fluid penetration of tedizolid: a case report.JAC-antimicrobial resistance · 2025Article
- Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood-brain barrier disruption.Clinical and translational science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Penetration of antimicrobial treatments into the cerebrospinal fluid is essential to successfully treat infections of the central nervous system. This penetration is hindered by different barriers, including the blood-brain barrier, which is the most impermeable. However, inflammation may lead to structural alterations of these barriers, modifying their permeability. The impact of blood-brain barrier disruption on linezolid and tedizolid (antibiotics that may be alternatives to treat nosocomial meningitis) penetration in cerebrospinal fluid (CSF) remains unknown. The aim of this study is to evaluate the impact of blood brain barrier disruption on CSF penetration of linezolid and tedizolid. Female C57BI/6 J mice were used. Blood-brain barrier disruption was induced by an intraperitoneal administration of lipopolysaccharide. Linezolid (40 mg/kg) or tedizolid-phosphate (20 mg/kg) were injected intraperitoneally. All the plasma and CSF samples were analyzed with a validated UPLC-MS/MS method. Pharmacokinetic parameters were calculated using a non-compartmental approach based on the free drug concentration. The penetration ratio from the plasma into the CSF was calculated by the AUC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.